Clinical trials: Oligometastatic
Oligometastatic Prostate Carcinoma
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for…
- Trial name
- NCT05707468
- Testing
- ADT combined with abiraterone, neoadjuvant hormone and RT
- Where
- 6 sites in China
- Volunteers
- 200 people
- Sponsor
- Changhai Hospital
Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic…
- Trial name
- NCT05917431
- Testing
- SBRT plus tislelizumab and regorafenib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Colon Cancer, Rectal Cancer
Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer
Patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and more recently stereotactic body…
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- tomoligo (NCT00807313)
- Where
- Belgium
- Volunteers
- 53 people
- Sponsor
- Universitair Ziekenhuis Brussel
Oligometastatic Disease
Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma
- Trial name
- NPC-CR01 (NCT05128201)
- Testing
- consolidative radiotherapy
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Extensive-stage Small-cell Lung Cancer
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with…
- Trial name
- NCT06223711
- Testing
- Thoracic Radiochemotherapy, durvalumab, Stereotactic radiotherapy of further tumor locations
- Where
- 5 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Universität des Saarlandes
Lung Neoplasms, Non-Small Cell Lung Cancer
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer
Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation.
- Trial name
- PTR-2 (NCT07738172)
- Testing
- Primary Tumor Resection, Osimertinib
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- National Taiwan University Hospital
Bone Cancer
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
- Trial name
- NCT02880319
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- oligo-mets (NCT02716974)
- Testing
- Leuprolide Acetate, Bicalutamide, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Neoplasms
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris…
- Trial name
- NCT05299606
- Testing
- Transbronchial Microwave Ablation
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Ethicon, Inc.
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
The present study aims to optimize the use of systemic therapy relative to local tumor ablation in a prospective randomized clinical trial and to validate the existence and characterize the clinical and pathology phenotype of…
- Trial name
- NCT04031378
- Testing
- Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation, Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Fundacao Champalimaud
Radiation Therapy, SBRT
SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy
Thisi is an Interventional drug-free randomized 1:1 open-label, multicenter, phase 3 trial in patients with first-line metastatic pancreatic cancer.
- Conditions
- Radiation Therapy, SBRT, Pancreatic Cancer Metastatic
- Trial name
- SENECA (NCT06946420)
- Testing
- SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy, Standard systemic therapy (chemotherapy) without RT/SBRT
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oligometastatic Disease
Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare Tumors
This prospective observational study aims to investigate the effectiveness and safety of SBRT in the management of oligometastases from rare tumors.
- Trial name
- PROMPT (NCT05903261)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Clinico Humanitas
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02364557
- Testing
- Stereotactic Body Radiotherapy, Surgery
- Where
- 162 sites in United States, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- NRG Oncology
Survival Outcomes
Effectiveness of Surgery for Improving Survival in Oligometastatic Breast Cancer Patients
Breast cancer is the most common malignancy in women, with stage IV disease at diagnosis in 5-10% of cases. Oligometastatic breast cancer (OMBC), defined as limited metastases (≤3-5 in ≤1-2 organs), may have better outcomes.
- Trial name
- SASI-MBC (NCT07586319)
- Testing
- surgery in accordance with current clinical guidelines, modified radical mastectomy or breast conservation surgery
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Sharif Medical Research Center
Non-small Cell Lung Cancer Metastatic
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer
- Trial name
- IMCORT-2 (NCT05472467)
- Testing
- Camrelizumab, stereotactic body radiation therapy, Chemotherapy
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Oligometastatic Hormone-Sensitive Prostate Cancer, Prostate Adenocarcinoma
Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy
MAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate…
- Trial name
- MAZINGA (NCT07766486)
- Testing
- Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Esophageal Cancer
Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer
Participants in this study will have esophageal cancer that has spread (metastasized) to other parts of the body either at initial diagnosis (synchronous) or after the cancer returned following treatment (recurrent).
- Trial name
- NCT07330583
- Testing
- Stereotactic body radiation treatment (SBRT)
- Volunteers
- 22 people
- Sponsor
- AHS Cancer Control Alberta
Central Thorax Cancer, Liver Cancer
Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
The purpose of this research study is evaluate whether it's feasible to give radiation therapy using an MRI-guided adaptive technique.
- Conditions
- Central Thorax Cancer, Liver Cancer, Non-Liver Abdominal Cancer
- Trial name
- NCT02264886
- Testing
- MRI-guided stereotactive body radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute